Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
| (A)
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH |
131624182 | 4 | Yes | 0 | 0 | |
| (B)
MEMORIAL HOSPITAL FOR CANCER & ALLIED DISEASES |
131624082 | 3 | Yes | 0 | 0 | |
| (C)
MEMORIAL SLOAN-KETTERING CANCER CENTER |
131924236 | 3 | Yes | 0 | 0 | |
| (D)
LOUIS V GERSTNER JR GRADUATE SCHOOL OF BIOMEDICAL SCIENCES |
202212588 | 2 | Yes | 0 | 0 | |
|
Total 4
|
||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 484,699,242 | 514,556,000 | 591,422,434 | 468,105,011 | 446,134,773 | 2,504,917,460 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 484,699,242 | 514,556,000 | 591,422,434 | 468,105,011 | 446,134,773 | 2,504,917,460 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 53,379,670 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 2,451,537,790 | |||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 484,699,242 | 514,556,000 | 591,422,434 | 468,105,011 | 446,134,773 | 2,504,917,460 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 201,917,796 | 100,111,000 | 190,676,000 | 123,653,294 | 129,384,000 | 745,742,090 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 0 | |||||
| 11 | Total support. Add lines 7 through 10 | 3,250,659,550 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | 0 | |||
| 2 | Recoveries of prior-year distributions | 2 | 0 | |||
| 3 | Other gross income (see instructions) | 3 | 0 | |||
| 4 | Add lines 1 through 3 | 4 | 0 | |||
| 5 | Depreciation and depletion | 5 | 0 | |||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | 0 | |||
| 7 | Other expenses (see instructions) | 7 | 0 | |||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | 0 | |||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | 0 | |||
| b | Average monthly cash balances | 1b | 0 | |||
| c | Fair market value of other non-exempt-use assets | 1c | 0 | |||
| d | Total (add lines 1a, 1b, and 1c) | 1d | 0 | |||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): 0 |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | 0 | |||
| 3 | Subtract line 2 from line 1d | 3 | 0 | |||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | 0 | |||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | 0 | |||
| 6 | Multiply line 5 by 0.035 | 6 | 0 | |||
| 7 | Recoveries of prior-year distributions | 7 | 0 | |||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | 0 | |||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | 0 | |||
| 2 | Enter 85% of line 1 | 2 | 0 | |||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | 0 | |||
| 4 | Enter greater of line 2 or line 3 | 4 | 0 | |||
| 5 | Income tax imposed in prior year | 5 | 0 | |||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | 0 | |||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | 0 |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | 0 |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | 0 |
| 4 Amounts paid to acquire exempt-use assets | 4 | 0 |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | 0 |
| 6 Other distributions (describe in Part VI). See instructions | 6 | 0 |
| 7Total annual distributions. Add lines 1 through 6. | 7 | 0 |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | 0 |
| 9 Distributable amount for 2020 from Section C, line 6 | 9 | 0 |
| 10 Line 8 amount divided by Line 9 amount | 10 | 0 % |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2020 |
(iii) Distributable Amount for 2020 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2020 from Section C, line 6 | 0 | |||
|
2
Underdistributions, if any, for years prior to 2019 (reasonable cause required-- explain in Part VI). See instructions. |
0 | |||
| 3 Excess distributions carryover, if any, to 2020: | ||||
| a From 2015.......0 | ||||
| b From 2016.......0 | ||||
| c From 2017.......0 | ||||
| d From 2018.......0 | ||||
| e From 2019.......0 | ||||
| fTotal of lines 3a through e | 0 | |||
| g Applied to underdistributions of prior years | 0 | |||
| h Applied to 2020 distributable amount | 0 | |||
|
i
Carryover from 2015 not applied (see instructions) |
0 | |||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | 0 | |||
| 4Distributions for 2020 from Section D, line 7: | ||||
| $ 0 | ||||
| a Applied to underdistributions of prior years | 0 | |||
| b Applied to 2020 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | 0 | |||
|
5
Remaining underdistributions for years prior to 2020, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
0 | |||
|
6
Remaining underdistributions for 2020. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
0 | |||
|
7 Excess distributions carryover to 2021. Add lines 3j and 4c. |
0 | |||
| 8 Breakdown of line 7: | ||||
| a Excess from 2016.....0 | ||||
| b Excess from 2017.....0 | ||||
| c Excess from 2018.....0 | ||||
| d Excess from 2019.....0 | ||||
| e Excess from 2020.....0 | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|---|
| SUPPORTED ORGANIZATIONS | SUPPORT FROM THE SUPPORTING ORGANIZATIONS RELATE PRINCIPALLY TO THE SHARING OF CERTAIN FACILITIES, EQUIPMENT, PERSONNEL COSTS, EDUCATION, INSURANCE AND ALLOCATIONS. AMOUNTS DUE TO OR DUE FROM AFFILIATES RESULTING FROM THESE SERVICES DO NOT BEAR INTEREST. |
| SUPPORTING ORGANIZATIONS | NAME OF SUPPORTING ORGANIZATION EIN TYPE S.K.I. REALTY 13-3389586 12a MSK INSURANCE US 83-0363317 12a MSKCC PROTON INC. 35-2397819 12a MSKCC PROPERTIES, LLC. 35-2464610 12a |
| Software ID: | |
| Software Version: |
| Return Reference | Explanation |
|---|---|
| NONDISCRIMINATORY POLICY | THE SCHOOL'S NONDISCRIMINATORY POLICY IS PUBLICIZED ON ITS WEB SITE: https://www.sloankettering.edu/gerstner/admissions/requirements ALL APPLICANTS TO THE LOUIS V. GERSTNER JR., GRADUATE SCHOOL OF BIOMEDICAL SCIENCES ARE CONSIDERED ON THE BASIS OF MERIT. THE SCHOOL DOES NOT DISCRIMINATE ON THE BASIS OF GENDER, RACE, COLOR, CREED, RELIGION, AGE, NATIONAL ORIGIN, DISABILITY, VETERAN STATUS, MARITAL STATUS, SEXUAL ORIENTATION, OR CITIZENSHIP STATUS IN ACCORDANCE WITH INSTITUTIONAL POLICY AND IN COMPLIANCE WITH THE REQUIREMENTS OF THE CIVIL RIGHTS ACT, THE EDUCATION AMENDMENTS, THE REHABILITATION ACT, THE AGE DISCRIMINATION ACT, AND THE AMERICANS WITH DISABILITIES ACT. EXCISE TAX ON NET INVESTMENT INCOME THE LOUIS V GERSTNER JR, GRADUATE SCHOOL OF BIOMEDICAL SCIENCES DOES NOT MEET THE CRITERIA OF SECTION 4968 AND, THEREFORE, IS NOT SUBJECT TO THE EXCISE TAX ON NET INVESTMENT INCOME. |
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| PART VI, LINE 2 | FOR THE TAX YEAR 2020, THE FOLLOWING BUSINESS RELATIONSHIPS WERE REPORTED: 1. DIRECTORS ELLEN V. FUTTER, LOUIS V. GERSTNER JR. AND PETER J. SOLOMON 2. DIRECTORS ALEXANDER T. ROBERTSON AND CLIFTON S. ROBBINS 3. DIRECTORS ELLEN V. FUTTER AND RICHARD I. BEATTIE 4. DIRECTORS WILLIAM FORD AND HENRY FERNANDEZ. PART VI, LINES 6-7 THE ARTICLES OF INCORPORATION AND BY-LAWS WERE REVIEWED TO DETERMINE THAT THE SUPPORTED ORGANIZATIONS OUTLINED IN SCHEDULE-A HAVE THE POWER TO ELECT OR APPOINT MEMBERS TO THE BOARD OF THE SUPPORTING ORGANIZATIONS. MEMORIAL SLOAN-KETTERING CANCER CENTER, EIN 13-1924236, (MSK), IS THE SINGLE MEMBER OF THE PROSTATE CANCER CLINICAL TRIALS CONSORTIUM LLC, PCCTC, WHO HAS ELECTED TO BE TREATED AS A DISREGARDED ENTITY OF MSK FOR TAX PURPOSES AND MSKCC PROTON, INC. WHO HAS ALSO ELECTED TO BE TREATED AS A CORPORATION FOR TAX PURPOSES. MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES EIN 13-1624082, (MEM), IS THE SINGLE MEMBER OF MSKCC PROPERTIES LLC, WHO HAS ELECTED TO BE TREATED AS A CORPORATION FOR TAX PURPOSES. PART VI, LINE 11B PRIOR TO FILING THE RETURN, A REVIEW OF THE 990 WAS CONDUCTED BY THE SR. VP OF FINANCE AND THE CHIEF FINANCIAL OFFICER. IT IS THEN PRESENTED TO, AND REVIEWED BY, THE JOINT AUDIT COMMITTEE OF THE BOARD. THE JOINT AUDIT COMMITTEE REFERS THE FORM 990 TO THE FULL BOARD, AND A COPY IS PROVIDED TO EACH BOARD MEMBER FOR FURTHER REVIEW. MEMORIAL SLOAN-KETTERING'S FORM 990 IS REVIEWED BY OUTSIDE COUNSEL AND IS PREPARED IN CONJUNCTION WITH ERNST AND YOUNG, LLP. |
| PART VI, LINE 12C | In 2020, MSK's conflict of interest (COI) program was implemented through three comprehensive policies for Memorial Sloan Kettering Cancer Center, Memorial Hospital for Cancer and Allied Diseases and Sloan-Kettering Institute for Cancer Research, which are outlined below: 1. Conflict of Interest and Commitment Policy (the "Individual COI Policy"). a. The Individual COI Policy applied to: (i) physicians and scientists with academic appointments at any level; (ii) any clinical provider who could independently write orders or prescriptions; (iii) individuals whose roles included the design, conduct or reporting of research and/or were engaged in human subject research; (iv) administrative employees with independent authority to make purchasing decisions or who were otherwise able to bind, negotiate on behalf, or execute agreements on behalf of, MSK; and (v) individuals that served on MSK institutional committees with responsibility for oversight of research, formulary, or purchasing decisions. b. MSK's Compliance COI Office ("Compliance") and the institutional conflict of interest committee (the "MSK COI Committee") were responsible for the administration of this policy, under the oversight of the newly-created committee of the Board (the "Board COI Committee") dedicated exclusively to discharging the Board's responsibility and authority over MSK's conflicts of interest program. c. Upon becoming covered by the Individual COI Policy, annually thereafter and/or as new significant interests arose, an individual was required to disclose financial interests and external relationships and activities ("interests"), whether paid or unpaid, that reasonably appeared to be related to the individual's institutional responsibilities. Covered Persons were required to disclose interests for themselves and immediate family members. d. Depending on the circumstances and based on established criteria, disclosed interests were reviewed by Compliance, the MSK COI Committee, MSK COI Committee designee(s), and/or the Board COI Committee to determine whether an individual conflict of interest existed or presented the perception thereof (i.e. whether an individual financial interest could directly and significantly impact an individual's institutional responsibilities, or an individual's interest could be directly and significantly impacted by their institutional responsibilities). e. The policy required any individual conflict of interest to be managed, reduced or eliminated. When a conflict of interest determination was made, the MSK COI Committee, the MSK COI Committee designee(s), or the Board COI Committee, as applicable, determined how to address it. For those conflicts deemed manageable, management strategies implemented included disclosure of the interest in relevant publications, presentations, consent forms, and educational materials; recusal and/or other limitation on role; independent oversight by a disinterested senior personnel member or committee; and temporary or permanent reduction, divestiture, relinquishment, or termination of an individual's interest. 2. Institutional Conflict of Interest Policy (the "Institutional COI Policy"). a. The Institutional COI Policy applied to financial interests and relationships ("interests") held by MSK as an institution, as well as those financial interests and relationships ("interests") held by five senior executive officers deemed "Institutional Officials,their immediate family members. Institutional Officials included the President and Chief Executive Officer, the Physician-In-Chief and Chief Medical Officer, the Chief Operating Officer, the Chief Financial Officer, and the Director of the Sloan-Kettering Institute for Cancer Research. b. Institutional interests held by MSK were made available to Compliance through regular reports from and ongoing engagement with relevant MSK departments. Institutional interests held by Institutional Officials were disclosed through the process described above in the Individual COI Policy, as well as the process described below in the Board COI Policy. c. The MSK COI Committee or MSK COI Committee designee(s) were responsible for determining whether an institutional conflict of interest existed; i.e. whether the institutional interest held by MSK or an Institutional Official (or their immediate family members) could, or could reasonably be perceived to, directly and significantly affect the design, conduct, reporting, review, or oversight of MSK research or the outcome of an MSK activity or decision. d. The policy required any institutional conflict of interest to be managed, reduced or eliminated. When an institutional conflict of interest determination was made, the MSK COI Committee and/or the MSK COI Committee designee(s) determined how to address it. For those conflicts deemed manageable, management strategies implemented included recusal of the applicable Institutional Official from decision-making regarding the arrangement and disclosure to relevant personnel; disclosure of the interest in relevant publications, presentations, consent forms, and educational materials; independent oversight by a disinterested senior personnel member or committee; and temporary or permanent reduction, divestiture, relinquishment, or termination of MSK's or an Institutional Official's institutional interest. 3. Boards of Governing Trustees Conflict of Interest Policy (the "Board COI Policy"). a. The Board COI Policy applied to Board members, officers, and other MSK senior leadership. Individuals covered by the Board COI Policy were required to disclose financial interests and relationships, as defined by the policy, annually and on an ongoing basis. Other entities in the same tax-exempt group had overlapping officers and Board members as described in Schedule O; such persons reported financial interests through this or related processes. b. The Board COI Committee was responsible for determining whether any interest disclosed under the Board COI Policy gave rise to a conflict of interest. The policy required that the members of the Board COI Committee vote, without the individual with the potential conflict present, to determine whether a conflict of interest existed. All members participating in the vote were required to be disinterested with respect to the transaction, arrangement, or relationship. c. The covered individual with the conflict of interest could make a presentation to the Board COI Committee, but could not participate in or influence the discussion of, or vote on, the proposed transaction, arrangement, or relationship. The existence and resolution of any conflict of interest, along with associated determinations made and votes taken, were required to be documented in writing. d. For any transaction, arrangement, or relationship that involved a conflict of interest, a conflict management plan could be implemented if doing so was in the best interests of MSK. Management plans could require disclosure, recusal or other limitation of role, independent oversight and confidentiality. |
| PART VI, LINE 15 | MEMORIAL SLOAN-KETTERING CANCER CENTER (MSKCC) IS COMMITTED TO ENSURING THAT ITS EXECUTIVE COMPENSATION PROGRAM ADHERES TO THE ESTABLISHED STANDARDS OF REGULATORY COMPLIANCE AND BEST CORPORATE GOVERNANCE. THE MSKCC BOARD OF TRUSTEES AND GOVERNING TRUSTEES HAS CHARGED THE JOINT HUMAN RESOURCES COMMITTEE (WHICH IS COMPOSED ENTIRELY OF INDEPENDENT BOARD MEMBERS WITH NO CONFLICTS OF INTEREST IN REGARD TO EXECUTIVE COMPENSATION) WITH MAKING ALL DECISIONS RELATED TO COMPENSATION FOR OFFICERS AND KEY EMPLOYEES. THE COMMITTEE REVIEWS THE TOTAL COMPENSATION OF THE INDIVIDUALS, INCLUDING BOTH CURRENT AND DEFERRED COMPENSATION, AND ALL EMPLOYEE BENEFITS, ON AN ANNUAL BASIS TO ENSURE THAT THE TOTAL COMPENSATION OF EACH OFFICER AND KEY EMPLOYEE IS REASONABLE. TO ASSIST IN THE COMPLETION OF ITS RESPONSIBILITIES, THE COMMITTEE ENGAGES THE SERVICES OF A NATIONALLY RECOGNIZED CONSULTING FIRM SPECIALIZING IN EXECUTIVE COMPENSATION FOR NOT-FOR-PROFIT HEALTHCARE ORGANIZATIONS. EACH YEAR THE COMMITTEE REVIEWS A COMPREHENSIVE REPORT PREPARED BY THE FIRM THAT INCLUDES MARKET DATA FOR FUNCTIONALLY COMPARABLE ROLES IN COMPARABLE ORGANIZATIONS (I.E., NOT-FOR-PROFIT ACADEMIC/RESEARCH MEDICAL CENTERS, ESPECIALLY THOSE SHARING A MISSION SIMILAR TO MSKCC, WITH OTHER HEALTHCARE SECTORS CONSIDERED ON A SELECTED BASIS) AND SUMMARIZES THE RELATIVE MARKET POSITION OF EACH EXECUTIVE'S TOTAL COMPENSATION. THE LAST REVIEW WAS MARCH 2020, WHICH SET THE COMPENSATION FOR THE PERIOD APRIL 2020 TO MARCH 2021. ADDITIONALLY, A SENIOR MEMBER OF THE CONSULTING FIRM ATTENDS COMMITTEE MEETINGS TO PROVIDE INFORMATION AND TO RESPOND TO QUESTIONS BY THE MEMBERS OF THE COMMITTEE. COMPENSATION LEVELS ARE ESTABLISHED CONSIDERING THE MARKET DATA, AN ASSESSMENT OF PERFORMANCE, AND OTHER BUSINESS JUDGMENT FACTORS, CONSISTENT WITH MSKCC'S EXECUTIVE COMPENSATION PHILOSOPHY. THE COMMITTEE'S DECISIONS ARE MADE IN THE BEST INTERESTS OF MSKCC AND ARE INTENDED TO ENSURE THE RECRUITMENT AND RETENTION OF KEY EXECUTIVE TALENT, CONSISTENT WITH THE MARKET PRACTICES OF OTHER NOT-FOR-PROFIT HEALTHCARE ORGANIZATIONS OF COMPARABLE SCOPE, MISSION AND COMPLEXITY. THE COMMITTEE'S REVIEW PROCESS FOLLOWS THE INTERMEDIATE SANCTIONS GUIDELINES FOR QUALIFYING FOR THE REBUTTABLE PRESUMPTION OF REASONABLENESS UNDER SECTION 4958 OF THE INTERNAL REVENUE CODE OF 1986: - THE COMPENSATION ARRANGEMENT IS APPROVED IN ADVANCE BY AN "AUTHORIZED BODY" OF THE APPLICABLE TAX EXEMPT ORGANIZATION (I.E, THE COMMITTEE, WHICH IS COMPOSED ENTIRELY OF INDIVIDUALS WHO DO NOT HAVE A CONFLICT OF INTEREST WITHIN THE MEANING OF THE REGULATIONS UNDER SECTION 4958). - THE AUTHORIZED BODY OBTAINS AND RELIES UPON "APPROPRIATE DATA AS TO COMPARABILITY" PRIOR TO MAKING ITS DETERMINATION, FOR WHICH COMPARABILITY DATA ARE PROVIDED AND ANALYZED BY SULLIVAN, COTTER AND ASSOCIATES, INC., A WELL-REGARDED EXPERT IN THE AREA OF HEALTHCARE COMPENSATION. - THE COMMITTEE ADEQUATELY DOCUMENTS THE BASIS FOR ITS DETERMINATION CONCURRENTLY WITH MAKING THAT DETERMINATION, AGAIN AS REQUIRED IN THE REGULATIONS. |
| PART VI, LINE 19 | OUR AUDITED FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST. IN ADDITION, THE FINANCIAL STATEMENTS CAN BE ACCESSED AT THE FOLLOWING WEB ADDRESS: WWW.DACBOND.COM. THE INSTITUTION HAS ENGAGED DAC BOND AS OUR INVESTOR RELATIONS AND DISCLOSURE/DISSEMINATION AGENT. THE INFORMATION AVAILABLE ON THIS WEB SITE INCLUDES AUDITED FINANCIAL STATEMENTS, QUARTERLY UNAUDITED FINANCIAL STATEMENTS AND THE BOND OFFERING STATEMENTS FOR ALL OUR DEBT ISSUES. IN ADDITION, COPIES OF THE GROUP 990 AND FILED 990T ARE ALSO AVAILABLE. THE CONFLICT OF INTEREST AND COMMITMENT POLICY IS AVAILABLE TO THE PUBLIC UPON REQUEST AND IT ALSO CAN BE FOUND AT THE FOLLOWING INSTITUTIONAL WEB SITE: WWW.MSKCC.ORG. GOVERNING DOCUMENTS SUCH AS THE ARTICLES OF INCORPORATION AND CORPORATE BY-LAWS ARE NOT MADE AVAILABLE TO THE PUBLIC. |
| PART VII, SECTION A | THIS IRS FORM 990 IS FILED UNDER GROUP EXEMPTION NUMBER 3475, EIN 91-2154267. THE ATTACHED LIST REPRESENTS MEMBERS FROM THE GOVERNING BOARDS OF THE FOLLOWING AFFILIATED INSTITUTIONS THAT MAKE UP OUR EXEMPT GROUP: MEMORIAL SLOAN-KETTERING CANCER CENTER (MSK) EIN 13-1924236, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES (MEM) EIN 13-1624082, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (SKI) EIN 13-1624182, S.K.I. REALTY, INC. (SKR) EIN 13-3389586, LOUIS V. GERSTNER JR. GRADUATE SCHOOL OF BIOMEDICAL SCIENCES (SKG) EIN 20-2212588, MSK INSURANCE US, INC. (MVI) EIN 83-0363317, AND MSKCC PROTON INC.,(MPI) EIN 35-2397819. ALSO INCLUDED IN THE GROUP IS MSK PROPERTIES LLC. EIN 35-2464610 WITH MEMORIAL HOSPITAL BEING THE SOLE MEMBER. MEMORIAL SLOAN KETTERING BOARD OF GOVERNING TRUSTEES: RICHARD I. BEATTIE IAN COOK STANLEY F. DRUCKENMILLER ANTHONY B. EVNIN ROGER W. FERGUSON HENRY A. FERNANDEZ WILLIAM E. FORD RICHARD N. FOSTER STEPHEN FRIEDMAN ELLEN V. FUTTER LOUIS V. GERSTNER, JR. JONATHAN N. GRAYER BENJAMIN W. HEINEMAN, JR. WILLIAM HELMAN, EFFECTIVE APRIL 2020 MARGARET KEANE, EFFECTIVE APRIL 2020 MARIE-JOSEE KRAVIS, VICE CHAIR OF THE BOARD JAMIE C. NICHOLLS, VICE CHAIR OF THE BOARD. JAMES G. NIVEN BRUCE C. RATNER CLIFTON S. ROBBINS, BOARD MEMBER & TREASURER ALEXANDER T. ROBERTSON JAMES D. ROBINSON III VIRGINIA M. ROMETTY ALAN D SCHNITZER STEPHEN C. SHERRILL PETER J. SOLOMON JOHN R. STRANGFELD SCOTT M. STUART, CHAIR OF THE BOARD CRAIG B. THOMPSON, M.D., BOARD MEMBER, PRESIDENT AND CHIEF EXECUTIVE OFFICER EMPLOYEE, NOT INDEPENDENT BOARD MEMBER DOUGLAS A. WARNER III, HONORARY CHAIR OF THE BOARD PETER A. WEINBERG 31 TOTAL BOARD MEMBERS 30 INDEPENDENT BOARD MEMBERS MEMORIAL HOSPITAL BOARD OF GOVERNING TRUSTEES: RICHARD I. BEATTIE, HONORARY CHAIRMAN OF THE BOARD IAN COOK STANLEY F. DRUCKENMILLER ANTHONY B. EVNIN ROGER W. FERGUSON HENRY A. FERNANDEZ WILLIAM E. FORD RICHARD N. FOSTER STEPHEN FRIEDMAN ELLEN V. FUTTER LOUIS V. GERSTNER, JR. JONATHAN N. GRAYER BENJAMIN W. HEINEMAN, JR. WILLIAM HELMAN, EFFECTIVE APRIL 2020 MARGARET KEANE, EFFECTIVE APRIL 2020 MARIE-JOSEE KRAVIS JAMIE C. NICHOLLS, CHAIR OF THE BOARD JAMES G. NIVEN BRUCE C. RATNER CLIFTON S. ROBBINS, BOARD MEMBER & TREASURER ALEXANDER T. ROBERTSON JAMES D. ROBINSON III VIRGINIA M. ROMETTY ALLAN D SCHNITZER STEPHEN C. SHERRILL PETER J. SOLOMON JOHN R. STRANGFELD SCOTT M. STUART CRAIG B. THOMPSON, M.D., BOARD MEMBER, CHIEF EXECUTIVE OFFICER EMPLOYEE, NOT INDEPENDENT BOARD MEMBER DOUGLAS A. WARNER III PETER A. WEINBERG 31 TOTAL BOARD MEMBERS 30 INDEPENDENT BOARD MEMBERS SLOAN KETTERING INSTITUTE BOARD OF GOVERNING TRUSTEES: RICHARD I. BEATTIE IAN COOK STANLEY F. DRUCKENMILLER ANTHONY B. EVNIN ROGER W. FERGUSON HENRY A. FERNANDEZ WILLIAM E. FORD RICHARD N. FOSTER STEPHEN FRIEDMAN ELLEN V. FUTTER LOUIS V. GERSTNER, JR., HONORARY CHAIRMAN OF THE BOARD JONATHAN N. GRAYER BENJAMIN W. HEINEMAN, JR. WILLIAM HELMAN, EFFECTIVE APRIL 2020 MARGARET KEANE, EFFECTIVE APRIL 2020 MARIE-JOSEE KRAVIS, CHAIR OF THE BOARD JAMIE C. NICHOLLS JAMES G. NIVEN BRUCE C. RATNER CLIFTON S. ROBBINS, BOARD MEMBER & TREASURER ALEXANDER T. ROBERTSON JAMES D. ROBINSON III VIRGINIA M. ROMETTY ALLAN D SCHNITZER STEPHEN C. SHERRILL PETER J. SOLOMON JOHN R. STRANGFELD SCOTT M. STUART CRAIG B. THOMPSON, M.D., BOARD MEMBER, CHIEF EXECUTIVE OFFICER EMPLOYEE, NOT INDEPENDENT BOARD MEMBER DOUGLAS A. WARNER III PETER A. WEINBERG 31 TOTAL BOARD MEMBERS 30 INDEPENDENT BOARD MEMBERS S.K.I. REALTY BOARD OF DIRECTORS: RICHARD I. BEATTIE LOUIS V. GERSTNER, JR. JAMES G. NIVEN, PRESIDENT CLIFTON S. ROBBINS SCOTT M. STUART, CHAIRMAN OF THE BOARD DOUGLAS A. WARNER III 6 TOTAL BOARD MEMBERS 6 INDEPENDENT BOARD MEMBERS GERSTNER GRADUATE SCHOOL BOARD OF TRUSTEES: RICHARD I. BEATTIE ELLEN V. FUTTER LOUIS V. GERSTNER, JR., CHAIRMAN OF THE BOARD MARIE-JOSEE KRAVIS ALLAN D SCHNITZER SCOTT M. STUART CRAIG B. THOMPSON, M.D. BOARD MEMBER, PRESIDENT, EMPLOYEE, NOT INDEPENDENT BOARD MEMBER DOUGLAS A. WARNER III 8 TOTAL BOARD MEMBERS 7 INDEPENDENT BOARD MEMBERS MSK INSURANCE U.S. BOARD OF DIRECTORS: DEBRA BERNS-EMPLOYEE NOT AN INDEPENDENT BOARD MEMBER KATHRYN MARTIN, DIRECTOR AND SECRETARY, EMPLOYEE NOT AN INDEPENDENT BOARD MEMBER STEPHEN C. SHERRILL, CHAIRMAN OF THE BOARD MARK SVENNINGSON, BOARD MEMBER AND PRESIDENT EMPLOYEE, NOT INDEPENDENT BOARD MEMBER JEFFREY P. JOHNSON, BOARD MEMBER AND VICE PRESIDENT MICHAEL P HARRINGTON, EMPLOYEE, NOT AN INDEPENDENT BOARD MEMBER 6 TOTAL BOARD MEMBERS 2 INDEPENDENT BOARD MEMBERS MSKCC PROTON INC., BOARD OF DIRECTORS: SIMON POWELL MD., EMPLOYEE NOT AN INDEPENDENT DIRECTOR 1 TOTAL DIRECTOR, 0 INDEPENDENT DIRECTORS |
| PART VII, SECTION B | AMOUNTS PAID TO INDEPENDENT CONTRACTORS INCLUDE AMOUNTS PAID TO SUBCONTRACTORS AS WELL AS REIMBURSABLE EXPENSES. PART XI RECONCILIATION OF NET ASSETS, OTHER NON-OPERATING (EXPENSE): CHANGE IN POSTRETIREMENT $ 426,371,000 OTHER NON-OPER EXPENSE (16,668,000) TOTAL $ 409,703,000 |
| Software ID: | |
| Software Version: |